Literature DB >> 7521312

Detection and distribution of hepatitis C-specific antigens in naturally infected liver.

K Blight1, R R Lesniewski, J T LaBrooy, E J Gowans.   

Abstract

Hepatitis C virus antigen expression was examined using peptide antibodies in liver tissue taken at biopsy from four chronic carriers of hepatitis C virus. Hepatitis C virus antigens E2/NS1, NS3, NS4 and NS5 were widespread in unfixed frozen liver sections and were present as distinct granules or foci within the cytoplasm of hepatocytes and in infiltrating lymphocytes in portal tracts. Fixation of frozen sections with 1% formalin improved the histological appearance of the tissue section without reducing the sensitivity of antigen detection. However, in tissue sections fixed in acetone, chloroform, carbon tetrachloride or methyl carnoys, detection of all hepatocyte-specific hepatitis C virus antigens was significantly reduced. Dual immunostaining of liver sections for lymphocyte cluster of differentiation markers and hepatitis C virus antigens determined that a high proportion of cluster of differentiation 20-positive B cells and cluster of differentiation 4-and cluster of differentiation 8-positive T cells, predominant in lymphoid aggregates, were positive for hepatitis C virus antigens.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521312

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

1.  Sequence analysis of the hepatitis C virus genome recovered from serum, liver, and peripheral blood mononuclear cells of infected chimpanzees.

Authors:  Y K Shimizu; H Igarashi; T Kanematu; K Fujiwara; D C Wong; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Hepatitis C virus infection of human hepatoma cell line 7721 in vitro.

Authors:  Z Q Song; F Hao; F Min; Q Y Ma; G D Liu
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 3.  Histopathology and detection of hepatitis C virus in liver.

Authors:  P J Scheuer; K Krawczynski; A P Dhillon
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Transcriptional activation of the interleukin-2 promoter by hepatitis C virus core protein.

Authors:  A Bergqvist; C M Rice
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Hepatitis C virus core protein induces an anergic state characterized by decreased interleukin-2 production and perturbation of mitogen-activated protein kinase responses.

Authors:  Sara Sundström; Seisuke Ota; Lina Y Dimberg; Maria G Masucci; Anders Bergqvist
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Different constitution of hepatitis C virus population in peripheral blood mononuclear cells and plasma in patients with type C chronic liver disease.

Authors:  A Okumura; K Yoshioka; T Aiyama; M Takayanagi; K Iwata; T Ishikawa; S Kakumu
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

7.  Pathomorphological Characteristics and Pathogenesis of Viral Hepatitis.

Authors:  Zsuzsa Schaff; Gábor Lotz; Rolf Schulte-Herman
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

8.  Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients.

Authors:  D Sansonno; A R Iacobelli; V Cornacchiulo; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

Review 9.  Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence.

Authors:  Dennis Revie; Syed Zaki Salahuddin
Journal:  Virol J       Date:  2011-07-11       Impact factor: 4.099

10.  The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage.

Authors:  Y Jin; L Fuller; M Carreno; K Zucker; D Roth; V Esquenazi; T Karatzas; S J Swanson; A G Tzakis; J Miller
Journal:  J Clin Immunol       Date:  1997-03       Impact factor: 8.542

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.